Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and ...

Investing.com — Kura Oncology, Inc. (NASDAQ: KURA )，一家市值5.75亿美元的临床阶段生物制药公司，宣布其关于KO-2806的临床前数据摘要已被美国癌症研究协会 (AACR)年会接受进行口头报告。根据 InvestingPro 分析，该公司在当前水平上似乎被低估，分析师设定的目标价格在每股10美元至40美元之间。该演讲计划于2025年4月28日进行 ...

After hours: March 25 at 7:31:01 PM EDT Loading Chart for KURA ...

Research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Kura Oncology in a research ...

Although it's now a lesser entry in the pipeline, KURA is continuing to develop the farnesyl transferase inhibitor tipifarnib. This agent is the subject of an ongoing study in combination with the ...

StockNews.com lowered shares of Kura Oncology (NASDAQ:KURA – Free Report) from a buy rating to a hold rating in a research ...

KO-2806 and tipifarnib; the expected timing and presentation of results and data from clinical trials; and the anticipated timing of submission of an NDA for ziftomenib. Factors that may cause ...

Such forward-looking statements include statements regarding, among other things, the potential of FTIs to augment the antitumor activities of targeted therapies and to overcome resistance; the ...

Osteoporosis is a metabolic bone disorder characterized by progressive decline of bone mass and bone quality, leading to bone fragility and an increased risk of fracture. Osteoporosis occurs when ...

Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, ...